On 10/9/24, Travere Therapeutics Inc (NASDAQ: TVTX) stock enjoyed a major increase of 15.6%, closing at $17.59. Moreover, this advance was accompanied by exceptionally high trading volume at 309% of normal. The stock has been exceptionally strong relative to the market over the last nine months and has risen 25.7% during the last week.
Current PriceTarget Research Rating
TVTX’s future returns on capital are forecasted to be in line with the cost of capital. Accordingly, the company is expected to continue to be Value Creation neutral.
Travere Therapeutics has a current Value Trend Rating of C (Neutral). The Value Trend Rating reflects very contradictory signals from PTR’s two proprietary measures of a stock’s attractiveness. Travere Therapeutics has a very low Appreciation Score of 7 but a very high Power Rating of 90, triggering the Neutral Value Trend Rating.
Rating Review
In light of this very positive price change we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment